Meet with our product experts in one-on-one virtual sessions
Set Up a Meeting
Amlodipine Besylate
Cardiovascular
Apixaban
Cardiovascular
Atorvastatin Calcium (Amorphous And Form 1)
Cardiovascular
Bempedoic Acid
Cardiovascular
Clopidogrel Bisulfate (Form 1)
Cardiovascular
Clopidogrel Bisulfate (Form 2)
Cardiovascular
Dabigatran Etexilate Mesylate
Cardiovascular
Doxazosin Mesylate
Cardiovascular
Ezetimibe
Cardiovascular
Fondaparinux Sodium
Cardiovascular
Lacidipine
Cardiovascular
Losartan Potassium
Cardiovascular
Mavacamten
Cardiovascular
Metoprolol Succinate
Cardiovascular
Ramipril
Cardiovascular
Rivaroxaban
Cardiovascular
Sacubitril / Valsartan
Cardiovascular
Tafamidis Free Acid
Cardiovascular
Tafamidis Meglumine
Cardiovascular
Ticagrelor
Cardiovascular
Treprostinil
Cardiovascular
Treprostinil Olamine
Cardiovascular
Valsartan
Cardiovascular
USPs of Cardiovascular API
- Well-controlled impurity profile (APIs meets current and future stringent impurity limits).
- Improved API flow property through controlled crystallization and process modifications to ease formulation development.
- Completely backward integrated on the KSMs to ensure uninterrupted supplies.
- Robust and sustainable supply chain.
- Eligible to file DMF’s globally in all the markets.
- Comprehensive assessment of synthetic routes and all toxicological attributes.
- All GTIs are controlled below TTC limits.
- Robust advanced analytical techniques to detect potential nitrosamine impurities.
- Process development through QBD approach.
- Customized particle sizes (PSD) to meet formulation requirements.
- Successful BE/dossier filing record of accomplishment in the markets.
- Multiple synthetic steps manufactured in-house.
- API and KSM process with no IP Issues.
- Comprehensive assessment of synthetic routes and all toxicological attributes.
Get access to Dr. Reddys largest Cardiovascular API portfolios to support your formulation success.
Dr. Reddy's offers a wide selection of cardiovascular active pharmaceutical ingredients used in the production of formulations to treat cardiovascular diseases. Our portfolio includes a broad class of cardiovascular molecules: HMG–CoA reductase inhibitors (statins), adenosine triphosphate-citrate lyase (ACL) inhibitors, calcium channel blockers, angiotensin II receptor antagonists, anticoagulants, beta-blockers, lipid modifiers, and others.
Dr. Reddy's is well-positioned to meet the global demands of Cardiovascular APIs. As a Cardiovascular API manufacturer and supplier, we follow a multistage synthesis to ensure supply chain sustainability and compliance with global regulatory requirements. In addition, Dr. Reddy's has established solid strategic sourcing, logistics partnerships and works closely with our customers to successfully manage the capacities of our manufacturing units ahead of launches.
Look at Dr. Reddy's broad selection of active pharmaceutical ingredients cardiovascular drugs used to treat cardiovascular diseases like hypertension, angina, benign prostate hyperplasia, pulmonary arterial hypertension, heredity angioedema, and many more.
Our portfolio includes a broad class of cardiovascular molecules:
- HMG–CoA reductase inhibitors (statins)
- Adenosine triphosphate-citrate lyase (ACL) inhibitors
- Calcium channel blockers
- Angiotensin II receptor antagonists
- Anticoagulants
- Beta-blockers
- Others
The global cardiovascular drugs market size is projected to hit around USD 231.7 billion by 2030 from valued at USD 155.6 billion in 2021 and growing at a CAGR of 4.52% from 2022 and 2030.
The global cardiovascular drugs market size is projected to hit around USD 231.7 billion by 2030 from valued at USD 155.6 billion in 2021 and growing at a CAGR of 4.52% from 2022 and 2030.
HMG–CoA inhibitors - decrease cholesterol levels. ACL Inhibitors - Direct inhibition of ACL by ETC-1002 lowers cytosolic acetyl CoA. Calcium channel blockers - prevent calcium from entering the cells of the heart & arteries. Angiotensin ii receptor antagonists - help relax veins & arteries to lower BP & make it easier for your heart to pump blood.
A control strategy has been defined using the QbD approach at every synthesis step and ensures that Dr. Reddy's APIs are free from potential genotoxic and carcinogenic impurities
Dr. Reddy's is well-positioned to meet the global demands of Cardiovascular APIs. We follow a multistage synthesis to ensure supply chain sustainability and compliance with global regulatory requirements. We established solid strategic sourcing and logistics partnerships and work closely with our customers to successfully manage the capacities of our manufacturing units ahead of launches.
Used to treat or improve symptoms of cardiovascular conditions including high blood pressure and heart failure.
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.